SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-035668
Filing Date
2022-10-28
Accepted
2022-10-28 16:06:07
Documents
49
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q abio-10q_20220930.htm   iXBRL 10-Q 1500612
2 EX-31.1 abio-ex311_8.htm EX-31.1 8580
3 EX-31.2 abio-ex312_6.htm EX-31.2 8583
4 EX-32.1 abio-ex321_7.htm EX-32.1 11235
5 GRAPHIC gkk44vndcqak000001.jpg GRAPHIC 1063
  Complete submission text file 0001564590-22-035668.txt   4219417

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA abio-20220930.xsd EX-101.SCH 27812
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE abio-20220930_cal.xml EX-101.CAL 29368
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE abio-20220930_def.xml EX-101.DEF 66599
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE abio-20220930_lab.xml EX-101.LAB 246994
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abio-20220930_pre.xml EX-101.PRE 173360
43 EXTRACTED XBRL INSTANCE DOCUMENT abio-10q_20220930_htm.xml XML 499327
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 221341889
SIC: 2835 In Vitro & In Vivo Diagnostic Substances